Acute myeloid leukaemia (AML) survival statistics

Five-year relative survival for acute myeloid leukaemia (AML) in men in England (14%) is similar to the average for Europe (15%). Wales (12%) and Scotland (13%) are also similar to the European average.[1] No five-year survival data is available for Northern Ireland. Across the European countries for which data is available, five-year relative survival in men ranges from 8% (Malta) to 20% (Belgium).[1]

Five-year relative survival for AML in women in England (16%) is below the average for Europe (18%). Scotland (18%) is similar to the European average.[1] No five-year survival data is available for Wales and Northern Ireland. Across the European countries for which data is available, five-year relative survival in women ranges from 7% (Estonia) to 23% (Belgium).[1

Acute Myeloid Leukaemia (C92.0, C92.4, C92.5, C92.6, C92.8, C93.0, C94.0 and C94.2), Age-Standardised Five-Year Relative Survival, Adults (Aged 15+), European Countries, 2000-2007

Data consists of both observed and predicted 5-year relative survival. Where sufficient follow-up was not available for recently diagnosed patients the period approach was used to predict 5-year cohort survival.

Possible explanations for persistent international differences in survival include differences in cancer biology, use of diagnostic tests and screening, stage at diagnosis, access to high-quality care, and data collection practices.[1]

References

  1. De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5 - a population-based study. Lancet Oncol 2014;15:23-34

About this data

Data is for: 29 European countries, patients diagnosed in 2000-2007 and followed up to 2008, acute myeloid leukaemia (C92.0, C92.4, C92.5, C92.6, C92.8, C93.0, C94.0 and C94.2).

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, Angel Building, 407 St John Street, London, EC1V 4AD or

Donate online

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.

Rate this page:

Currently rated: 1.3 out of 5 based on 3 votes
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page